-

Bruker Corporation to Present at Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the following virtual conferences:

BofA Securities 2021 Health Care Conference
Tuesday, May 11, 2021, at 11:00 a.m. Eastern Time
Frank Laukien, Chairman, President and Chief Executive Officer
Mark Munch, President, Bruker Nano Group

UBS Global Healthcare Virtual Conference
Monday, May 24, 2021, at 9:00 a.m. Eastern Time
Frank Laukien, Chairman, President and Chief Executive Officer
Mark Munch, President, Bruker Nano Group

Jefferies Virtual Healthcare Conference
Wednesday, June 2, 2021, at 8:00 a.m. Eastern Time
Frank Laukien, Chairman, President and Chief Executive Officer
Juergen Srega, President, Bruker CALID Group

Live audio webcasts of the virtual presentation and “fireside” sessions will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays will be posted on Bruker’s Investor Relations website after each event and will be available for 30 days following the presentation.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Miroslava Minkova
Senior Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: Investor.Reations@bruker.com

Industry:

Bruker Corporation

NASDAQ:BRKR
Release Versions
English

Contacts

Miroslava Minkova
Senior Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: Investor.Reations@bruker.com

More News From Bruker Corporation

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

BERLIN--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei...

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

SINGAPORE--(BUSINESS WIRE)--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF dis...

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

BERKELEY, Calif.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation. These capabilities strengthen research in chemistry, materials science, structural biology, and related fields across UC Berkeley an...
Back to Newsroom